Thanks Matt, I've got to take my chances and, as you 've said,...

Thanks Matt, I've got to take my chances and, as you 've said, there are only a few weeks left before a series of inflection points comes into play:

• Final GLP toxicology studies of PAT-DX1
• PAT-DX3 Master Cell Bank preparation AND Manufacturing process optimisation underway
• Experiments currently underway to evaluate the use of deoxymabs for synthetic lethal approaches and the delivery of gene-editing constructs

There may still be good opportunity to buy at this levels but IMO the more we move forward in the timeline the more chances are that - as Dr Campbell said in the last webinar - sh may get a "bit of surprise", a deal with those for which the current experiments are being carried out: BP.

NOT FINANCIAL ADVICE, DYOR